HighTower Advisors LLC grew its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 11.5% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 123,477 shares of the biotechnology company’s stock after purchasing an additional 12,706 shares during the period. HighTower Advisors LLC’s holdings in Arrowhead Pharmaceuticals were worth $2,401,000 at the end of the most recent reporting period.
Other hedge funds also recently made changes to their positions in the company. Squarepoint Ops LLC acquired a new stake in Arrowhead Pharmaceuticals during the second quarter valued at approximately $9,976,000. Avoro Capital Advisors LLC increased its holdings in shares of Arrowhead Pharmaceuticals by 3.9% in the second quarter. Avoro Capital Advisors LLC now owns 8,888,888 shares of the biotechnology company’s stock valued at $231,022,000 after buying an additional 333,333 shares in the last quarter. Assenagon Asset Management S.A. lifted its position in shares of Arrowhead Pharmaceuticals by 232.5% during the 3rd quarter. Assenagon Asset Management S.A. now owns 293,083 shares of the biotechnology company’s stock valued at $5,677,000 after acquiring an additional 204,933 shares during the last quarter. Millennium Management LLC boosted its stake in shares of Arrowhead Pharmaceuticals by 61.9% during the 2nd quarter. Millennium Management LLC now owns 529,251 shares of the biotechnology company’s stock worth $13,755,000 after acquiring an additional 202,280 shares in the last quarter. Finally, abrdn plc grew its holdings in shares of Arrowhead Pharmaceuticals by 61.3% in the 3rd quarter. abrdn plc now owns 401,146 shares of the biotechnology company’s stock worth $7,770,000 after acquiring an additional 152,476 shares during the last quarter. Institutional investors and hedge funds own 62.61% of the company’s stock.
Arrowhead Pharmaceuticals Stock Down 1.3 %
Arrowhead Pharmaceuticals stock opened at $21.85 on Friday. Arrowhead Pharmaceuticals, Inc. has a twelve month low of $17.05 and a twelve month high of $39.83. The company has a debt-to-equity ratio of 2.06, a quick ratio of 6.74 and a current ratio of 6.74. The firm has a market cap of $2.72 billion, a PE ratio of -4.35 and a beta of 0.91. The firm’s 50 day moving average price is $20.98 and its two-hundred day moving average price is $23.15.
Wall Street Analysts Forecast Growth
Get Our Latest Analysis on Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals Company Profile
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.
Featured Articles
- Five stocks we like better than Arrowhead Pharmaceuticals
- What Are Growth Stocks and Investing in Them
- FinWise Bancorp’s CEO Talks Strategy Behind Fintech Success
- Short Selling: How to Short a Stock
- Broadcom: Turning the Mag 7 Into 8 Trillion-Dollar Tech Giants
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- SoundHound AI: Can Its Meteoric Rise Sustain Into 2025?
Want to see what other hedge funds are holding ARWR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report).
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.